March 27, 2024
Mark FedelePresident of Eugia US LLC279 Princeton Hightstown RoadEast Windsor, NJ 08520Email: mfedele@eugiaus.comDirect: 732-917-2428 FOR IMMEDIATE RELEASE –March 22, 2024– East Windsor, New Jersey, Eugia US LLC (f/k/a AuroMedics Pharma LLC) has initiated a voluntary recall of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) – 10mL Vial to […]
February 29, 2024
Eugia US is pleased to welcome Tim Ryan, our newest Territory Business Manager covering Florida. Tim lives in the Tampa area and comes to us with several years of experience working with hospitals throughout the state of Florida. During his tenure, he’s had great success forging relationships with some of the largest IDNs and cancer centers in the […]
January 08, 2024
Eugia is excited to welcome Anita Varshney, Manager of Rebates and Government Pricing. In this role Anita will join our Commercial Sales Operations and Administration team, and will have the responsibility for commercial rebates and admin fees as well as government pricing and Medicaid. She comes to us with over 12 years of pharmaceutical experience in […]
November 30, 2023
Eugia is pleased to welcome Toni Picone, Sr. Marketing Director of Marketing Operations. In this role Toni will join our commercial leadership team, leading our marketing team in all elements of marketing operations including P&L management, new product launches, business development, analytics and promotional communications. Toni brings more than 20 years of experience to this […]
November 03, 2023
Eugia US is pleased to welcome Shannon Rieke, our newest Mid-Atlantic Territory Business Manager. She comes to us with multiple years of experience and will be covering MD, VA, DC, NC, and SC. Shannon will be a valued asset to the Eugia US team and her customers as she brings with her a wealth of knowledge of the […]
October 18, 2023
Eugia US is excited to welcome Krishna Patel, Associate, QA Product Complaint & Recall. Krishna is an experienced healthcare professional with more than 10 years of experience as Drug Safety Associate, Pharmacology Associate, Quality Chemist and Pharmacy Technician. Over the years, she has been successful in processing ICSR for Product Complaints, serious adverse events (SAE) […]
September 25, 2023
Eugia US is pleased to welcome David Anderson, Strategic Account Manager. David resides in Phoenix, Arizona. He has over 15 years of experience selling pharmaceuticals (Generic Injectables, Biosimilars and 503B) specializing in IDNs and National Accounts. We are thrilled to have David on our team and bring his generic injectable expertise along with his customer relationships to grow […]
September 22, 2023
Eugia US is pleased to welcome Kim Stahl, our newest Territory Business Manager covering Texas and Oklahoma. Kim resides in Katy, TX, with her four children. She has been in the pharmaceutical industry for 15 years, specializing in oncology, generic injectables, GPO Knowledge, and handling large IDNs. Prior to Eugia, she worked for Fresenius-Kabi, which awarded […]
August 30, 2023
Eugia US is pleased to welcome Michael Tedesco, Business Analytics and Insights. Michael lives with his wife in Morristown, New Jersey. He has been in the pharmaceutical industry for 20 years holding multiple roles in commercial analytics, sales operations, data analysis, and portfolio management. Prior to Eugia, he has worked for IQVIA, Sandoz, Mylan, and Johnson & Johnson. […]
August 15, 2023
Visit Eugia at National Pharmacy Purchasing Association’s (NPPA) annual meeting, August 14-17, 2023 at Horseshoe Las Vegas. Eugia will be in Booth 213 and will be highlighting several important New Product Launches: Bendamustine, Diltiazem, Methylprednisolone (MDV), Tirofiban, Carboprost, Plerixafor, and Vancomycin. Additionally, company leadership will be present to meet customers and answer questions including:
August 04, 2023
Eugia US is pleased to announce the newest launch of Vancomycin Hydrochloride for Injection USP, 1.25 g/vial and 1.5 g/vial, Single Dose Vial. Indicated in adults and pediatric patients (neonates and older) for the treatment of: This New Product Launch demonstrates our commitment to meet our customer needs by providing high-quality products, flexible pricing, and consistent […]
May 25, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, Single-Dose Vials. Indications for this product include: Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not […]
May 01, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) [Single-Dose Flexible Container] Indications for this product include: Refer to package insert for full prescribing information.
April 17, 2023
On April 6, 2023, FDA withdrew its approval of generic Makena (hydroxyprogesterone caproate injection) manufactured by Eugia US. Eugia US, therefore, is no longer selling or distributing the drug. The company is conferring with FDA about how to handle any returns, so please contact us before initiating any return of generic Makena manufactured by us. […]
April 13, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL) & 400 mg/5 mL (80 mg/mL) [Multi Dose Vial] Indications for this product include: For Intramuscular Administration: Refer to package insert […]
April 03, 2023
Eugia US is pleased to announce the promotions of three sales leaders. Effective today, Rob Bloomer has been promoted to Associate Director, Trade Relations, Acute. Also effective immediately, Kyle Grupas has been promoted to Regional Director, National Accounts and Sales, West and Katherine Bowman has been promoted to Regional Director, National Accounts and Sales, East. […]
March 29, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL (5 mg/mL), and 125 mg/25 mL (5 mg/mL), Single-Dose Vials. Indications for this product include: Refer to package insert for […]
February 13, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Hydralazine Hydrochloride Injection USP, 20 mg/mL Single-Dose Vials. Indications for this product include: It is used in severe essential hypertension when the drug cannot be given orally or when there is […]
February 02, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Voriconazole for Injection, 200 mg/Vial Single-Dose Vials. Indications for this product include: It is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and […]
January 03, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Azacitidine for Injection, 100 mg Single-Dose Vial. Indications for this product include: Indicated for the treatment of adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or […]
November 17, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. Indications for this product include: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients. […]
October 26, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL). Indications for this product include: Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo […]
September 26, 2022
August 22, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market: Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial FDA approved 8/22Refer to package insert for full prescribing information. Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Prefilled […]
August 15, 2022
Dear all, Today marks an exciting new chapter for our company as we formally begin the transition to a newspecialty business called Eugia. As part of this transition, AuroMedics will fall under our new parentcompany, Eugia Pharma Specialties Limited. Our new name combines “Eu,” a Greek prefix meaning “good” or “well”, along with “Hygia,” known […]
August 15, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Vasopressin Injection USP, 20 units/mL, I mL MDV. Indications for this product include: To increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Refer […]
July 20, 2022
Eugia US is pleased to announce that the company has received tentative approval from the US Food & Drug Administration (USFDA) to manufacture and market Plerixafor Injection 24 mg/1.2 mL. Indications for this product include: Indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection […]
July 14, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Prochlorperazine Edisylate Injection 10mg/2ml MDV. Indications for this product include: To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of […]
July 06, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/10 mL MDV. Indications for this product include: For Intramuscular and Intra-Articular use only. Intramuscular – Where oral therapy is not feasible: allergic […]
June 06, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Leuprolide Acetate Injection 14 mg/2.8 mL MDV. Each 14-day kit contains: One Leuprolide Acetate Injection 14 mg/2.8 mL multiple-dose vial Patient Instructions for Use14 disposable syringes 28 alcohol swab Indications for […]
May 25, 2022
Eugia Pharma Limited is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Pemetrexed for Injection, 100 mg, 500 mg, and 1,000 mg. Indications for this product include: With pembrolizumab and platinum chemotherapy, for initial treatment of patients with metastatic non-squamous NSCLC, with […]
May 02, 2022
Eugia Pharma Limited is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Bortezomib for Injection, 3.5 mg. Indications for this product include: Adult patients with multiple myeloma; Adult patients with mantle cell lymphoma. Refer to package insert for full prescribing information.
April 20, 2022
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Thiamine HCl Injection 200 mg/2 mL Multi-Dose Vials. Indications for this product include: Treatment of thiamine deficiency or beriberi. Also indicated in patients with established thiamine deficiency who cannot […]
March 21, 2022
Eugia Pharma Limited is pleased to announce that the company has received a first-cycle approval from the US Food & Drug Administration (USFDA) to manufacture and market Esmolol HCl in Sodium Chloride Injection 2,500 mg/250 mL and 2,000 mg/100 mL Single-Dose Containers (Bags). Indications for this product include: Rapid control of ventricular rate in patients […]
January 27, 2022
Vincent P. AndolinaEugia US.Vice President, Regulatory Affairs279 Princeton Hightstown RoadEast Windsor, NJ 08520vandolina@aurobindousa.comDirect 732-917-2436 FOR IMMEDIATE RELEASE – January 26, 2022 – East Windsor, New Jersey, Eugia US has initiated a voluntary recall of lot number CPB200013 of Polymyxin B for Injection USP, 500,000 Units/Vial, to the consumer level from the USA market due to […]
January 24, 2022
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL. Indications for this product include: Secondary hyperparathyroidism in adult patients with CKD on dialysis. Refer to package insert for full […]
October 15, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Arsenic Trioxide Injection 12 mg/6 mL. Indications for this product include: Induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have […]
September 02, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Daptomycin for Injection 500 mg. Indications for this product include: Complicated skin and skin structure infections; Staphylococcus aureus bloodstream infections (bacteremia) in adult patients; Staphylococcus aureus bloodstream infections (bacteremia) in […]
September 01, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials. Eugia’s product will be available in ready-to-use (RTU) injection preparation. The product shall be launched in the US market through […]
June 14, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection 50 mg/mL Single-Dose Vials. Indications for this product include: Clinically important hypotension occurring in the setting of anesthesia. Refer to package insert for full prescribing […]
April 12, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Nicardipine HCl Injection 25 mg/10 mL Single-Dose Vials. Indications for this product include: Short-term treatment of hypertension when oral therapy is not feasible or not desirable. Refer to package […]
February 09, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Isoproterenol HCl Injection 0.2 mg/1 mL and 1 mg/5 mL Ampoules. Indications for this product include: Mild or transient episodes of heart block that do not require electric shock […]
January 14, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Naloxone HCl Injection Prefilled Syringe 2 mg/2 mL. Indications for this product include: Complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids; […]
January 12, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fosaprepitant for Injection, 150 mg Single-Dose Vials. Indications for this product include: Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic […]
January 07, 2021
January 07, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Phenylephrine HCl Injection USP, 10 mg/mL Single-Dose Vials. Indications for this product include: Increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings […]
December 14, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose Flexible Containers (Bags). Indications for this product include: Sedation of initially intubated and mechanically ventilated […]
December 10, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sodium Nitroprusside Injection, 50 mg/2 mL Single-Dose Vials. Indications for this product include: Immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises; Producing controlled hypotension […]
December 08, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cyanocobalamin Injection, 1,000 µg/mL, 1 mL Vials. Indications for this product include: Vitamin B12 deficiencies due to malabsorption; Cyanocobalamin injection is also suitable for the vitamin B12 absorption test […]
November 02, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Irinotecan Hydrochloride Injection USP, 40 mg/2 mL (20 mg/mL), 100 mg/5 mL (20 mg/mL) and 300 mg/15 mL (20 mg/mL) Single-dose Vials. Indications for this product include: Component of […]
October 22, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olanzapine for Injection, 10 mg/vial, Single-dose Vials. Indications for this product include: Acute agitation associated with schizophrenia and bipolar I mania. Refer to package insert for full prescribing information […]
October 21, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen Injection 1,000 mg/100 mL Single-Dose Vials. Indications for this product include: Mild to moderate pain in adult and pediatric patients 2 years and older; Moderate to severe pain […]
September 03, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Milrinone Lactate in 5% Dextrose Injection, 20 mg/100 mL (200 mcg (0.2 mg)/mL) and 40 mg/200 mL (200 mcg (0.2 mg)/mL). Refer to package insert for full prescribing information.
July 07, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL) Ampules. Indications for this product include treatment of schizophrenia; to control nausea and vomiting; for relief of […]
July 06, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market for Verapamil Hydrochloride Injection USP, 5 mg/2 mL (2.5 mg/mL) and 10 mg/4 mL (2.5 mg/mL), Single-Dose Vials. Indications for this product include: Rapid conversion to sinus rhythm of […]
June 05, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL Single-dose Vial. Refer to package insert for full prescribing information.
May 08, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cisatracurium Besylate Injection USP, 20 mg/10mL MDV. Indications for this product include adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month […]
June 07, 2019
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexamethasone Sodium Phosphate Injection USP, 100 mg/10mL (10 mg/mL) Multi-dose Vial. Refer to package insert for full prescribing information.
December 06, 2018
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycopyrrolate Injection . Indications for this product include preoperative antimuscarinic to reduce salivary, tracheabronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and […]
December 06, 2018
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Argatroban in Sodium Chloride Injection 50 mg/50 mL . Indications for this product include Prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia; Anticoagulant in adult […]
September 26, 2018
Consumers rely on medication every day for many different health conditions. In fact, the CDC reports that nearly half of people surveyed from 2011-2014 used at least one prescription drug in the 30 days prior to the survey. Almost 80% of physician office visits, hospital outpatient visits, and emergency room visits involved drug therapy. There’s […]
July 31, 2018
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection, 250 mg/vial. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax® Injection of The Medicines Company. The estimated market size […]
July 30, 2018
For some patients, the high costs often associated with prescription drugs can make it hard to comply with a doctor’s directives. Many health conditions require that patients stay on a prescribed drug in order to reduce the severity of symptoms or live with less discomfort. When costs are a deterrent to consistent use of certain […]
June 26, 2018
On June 25, 2018 Eugia received FDA approval for Ertapenem for Injection which is indicated for treatment of moderate to severe infections caused by susceptible bacteria. This approved product has an estimated market size of $387 million for the twelve months ending April 2018 according to IMS. Click here for our Press release!
January 02, 2018
On December 27, 2017 Eugia received FDA approval for Fondaparinux Sodium Injection which is used to prevent deep vein thrombosis (DVT). This approved product has an estimated market size of $73 million for the twelve months ending October 2017 according to IMS. PR USFDA FA – Fondaparinux Sodium Injection
January 02, 2018
It is an East Windsor Township tradition to recognize businesses – how important they are to the community, how proud the township is of them and how they contribute to the community – every year, Mayor Janice Mironov said. There are three awards – the Business Beautification Award, the Community Service Award and the Community […]
December 18, 2017
Eugia has big plans in the coming years. Breaking into the oncology space is one piece of that puzzle. Follow the link below for additional information Eugia aims at cancer as it climbs the value chain
December 12, 2017
December 03 through 06 of 2017 marked the 75th year of the annual ASHP Midyear Clinical Meeting. With attendance rising to 25,000, this is the largest gathering of pharmacy professionals in the world. Eugia was proud to have our largest presence with a custom 20×30 foot booth, which helped showcase some of our most in demand products […]
December 11, 2017
On December 08, 2017 Eugia received FDA approval for Zoledronic Acid which is a bisphosphonate indicated for treatment of Paget’s disease of bone in men and women. Zoledronic Acid has an estimated annual market of $17.5 million according to IMS data running through October 2017.
November 03, 2017
On November 02, 2017 Eugia received FDA approval for Adenosine Injection Single-Dose Vials which is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. With an estimated total annual market of $17.3 million through June 2017 according to IMS data, this is an exciting addition to the Eugia portfolio.
October 31, 2017
On October 30, 2017 Eugia received FDA approval for Lidocaine HCl Injection Multiple-Dose Vials. Eugia currently markets the Single-Dose Vials and looks forward to the growth of this product family. This product has an estimated annual market size of $39.5 million through June 2017 according to IMS data.
October 26, 2017
On October 25, 2017 Eugia received FDA approval for Amiodarone HCl Injection which is an antiarrhythmic indicated as the initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (and hemodynamically unstable ventricular tachycardia) in patients refractory to other therapy. According to IMS data annual reporting through June 2017, the market size of this product is […]
September 14, 2017
Eugia could not be more excited to announce the opening of our brand new, state of the art facility located right in our headquarter’s backyard. Get the details and take a virtual tour by clicking the link below. Eugia opens new state of the art, fully automated, distribution center spanning across 59 acres of land […]
